Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ATOS US​

Atossa Therapeutics, Inc.(ATOS US)

$2.60-0.124.41%Ext:$2.58-0.020.77%(Market Closed · 23:51:54 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Atossa Therapeutics, Inc. — Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Steven C. Quay
Headquarters
Seattle, WA, US
IPO Date
Nov 8, 2012
Employees
16
Website
www.atossatherapeutics.com

Key Metrics

Price
$2.34
Market Cap
$23.34M
Revenue (TTM)
$0.00
Net Income (TTM)
$-9589000.00
EPS (TTM)
-1.11
P/E (TTM)
-0.62
P/B (TTM)
0.77
Dividend Yield
0.00%
ROE (TTM)
-31.45%
ROA (TTM)
-25.27%
Operating Margin
0.00%
Beta
1.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Website
www.atossatherapeutics.com
Location
Seattle, WA, US
Phone206 588 0256
Employees16
CEOSteven C. Quay
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 8, 2012

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(621)

Expand
  • 8-KEntry into a Material Definitive Agreement9 Oct
  • 8-KOther Events29 Sep
  • 8-KRegulation FD Disclosure18 Sep
  • 8-KResults of Operations and Financial Condition7 Aug
  • 10-QQ2ended 30 Jun 20267 Aug
  • 424B5Prospectus filing (Rule 424(b)(5))12 Jun
  • 8-KEntry into a Material Definitive Agreement11 Jun
  • 4Statement of changes in beneficial ownership14 May
  • 4Statement of changes in beneficial ownership14 May
  • 4Statement of changes in beneficial ownership14 May
  • 4Statement of changes in beneficial ownership14 May
  • 4Statement of changes in beneficial ownership14 May
  • 4Statement of changes in beneficial ownership14 May
  • 8-KFinancial Statements and Exhibits8 May
  • 10-QQ1ended 31 Mar 20268 May
  • 8-KSubmission of Matters to a Vote of Security Holders8 May
  • 8-KOther Events16 Apr
  • 4Statement of changes in beneficial ownership31 Mar
  • 4Statement of changes in beneficial ownership30 Mar
  • ARSAnnual report to security holders30 Mar

News

  • Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today19 Oct
  • Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value9 Oct
  • Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher29 Sep
  • Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging24 Sep
  • Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update7 Aug
  • Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer28 Jul

Mentions in Filings

  • … -listed international consumer foods company, from September 9 --- Table of Contents 2023 to August 2025. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of <strong>Atossa Therapeutics, Inc.</strong> (Nasdaq, ATOS), a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse’s experience includes 30 years of counseling innovative, rapid growth companies through all a …
    PLUS THERAPEUTICS, INC.Atossa Therapeutics, Inc.·DEF 14A - Definitive proxy statement·Q2 26·31 Mar
  • … ior to joining Altimmune, he briefly served as a financial consultant since July 2024. Prior to that, Mr. Weaver served as CFO of Cognito Therapeutics from September 2023 through June 2024, and as interim CFO of <strong>Atossa Therapeutics, Inc.</strong> (Nasdaq: ATOS) from June 2023 to September 2023. Prior to that, Mr. Weaver served as CFO of BiointelliSense from October 2022 through May 2023, CFO of Atai Life Sciences N.V. (Nasdaq: ATAI) from September 2020 th …
    Altimmune, Inc.Atossa Therapeutics, Inc.·DEF 14A - Definitive proxy statement·Q2 26·17 Mar
  • … ior to joining Altimmune, he briefly served as a financial consultant since July 2024. Prior to that, Mr. Weaver served as CFO of Cognito Therapeutics from September 2023 through June 2024, and as interim CFO of <strong>Atossa Therapeutics, Inc.</strong> (NASDAQ: ATOS) from June 2023 to September 2023. Prior to that, Mr. Weaver served as CFO of BiointelliSense from October 2022 through May 2023, CFO of Atai Life Sciences N.V. (NASDAQ: ATAI) from September 2020 th …
    Altimmune, Inc.Atossa Therapeutics, Inc.·PRE 14A - Preliminary proxy statement·Q2 26·6 Mar
  • … terprise Ltd. (NYSE:DDC), an NYSE-American-listed international consumer foods company, since September 2023. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of <strong>Atossa Therapeutics, Inc.</strong> (Nasdaq, ATOS), a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse’s experience includes 30 years of counseling innovative, rapid growth companies through all a …
    PLUS THERAPEUTICS, INC.Atossa Therapeutics, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q1 26·14 Jan
  • … terprise Ltd. (NYSE:DDC), an NYSE-American-listed international consumer foods company, since September 2023. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of <strong>Atossa Therapeutics, Inc.</strong> (Nasdaq, ATOS), a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse’s experience includes 30 years of counseling innovative, rapid growth companies through all a …
    PLUS THERAPEUTICS, INC.Atossa Therapeutics, Inc.·S-1 - Registration statement (general form)·Q1 26·9 Jan
  • … ior to joining Altimmune, he briefly served as a financial consultant since July 2024. Prior to that, Mr. Weaver served as CFO of Cognito Therapeutics from September 2023 through June 2024, and as interim CFO of <strong>Atossa Therapeutics, Inc.</strong> (NASDAQ: ATOS) from June 2023 to September 2023. Prior to that, Mr. Weaver served as CFO of BiointelliSense from October 2022 through May 2023, CFO of Atai Life Sciences N.V. (NASDAQ: ATAI) from September 2020 th …
    Altimmune, Inc.Atossa Therapeutics, Inc.·DEF 14A - Definitive proxy statement·Q3 25·15 Aug 2025

Key Stats

Trading

Px/Chg 1D$2.34 / +3.08%
Prev Close$2.53
% of 52Wk H13.02%
Avg Volume119.00K
Beta1.00
Mkt Cap23.34M
FD Mkt Cap25.14M

Float

Shrs Out/Float9.97M / 8.58M
Short Float0.08%
Days to Cover2.20
Stock Repurchased$0.00

Current Valuation

EV-8376500.00
EV/EBITDA0.22
EV/Sales0.00
P/B0.77
P/S0.00
FCF Yield-41.05%
ROE-31.45%
ROA-25.27%
Current Ratio4.92

Estimates

P/E-0.62
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-4.12-3.29-6.24-4.13-4.46-2.47
Price / Sales0.000.000.000.000.000.00
Price / Book Value1.260.752.061.471.240.78
Price / Free Cash Flow-5.07-4.26-8.96-5.00-4.63-2.47
ENTERPRISE VALUE METRICS
Enterprise Value22.3-21.799.434.27.5-8.0
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-0.700.78-3.17-1.24-0.690.84
Enterprise Value / EBIT-0.700.78-3.17-1.24-0.690.84

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—-0.0-0.0-0.0-0.0-
EBITDA14.1%-20.5-27.7-31.4-27.6-34.8
EBIT14.1%-20.5-27.7-31.4-27.6-34.8
Net Income14%-20.6-27.0-30.1-25.5-34.8
EPS (Diluted)10.6%-2.70-3.15-3.60-3.00-4.04
BALANCE SHEET
Cash & ST Inv-25.8%136.4110.988.571.141.3
Total Assets-23.8%141.3123.596.376.447.6
Total Liabilities27.5%3.15.65.25.08.3
Total Shareholder Equity-26.9%138.1118.091.071.539.4
CASH FLOW
Net Operating Cash Flow15.9%-16.5-20.8-20.9-21.0-29.8
Cap Ex26.4%-0.0-0.0-0.0-0.0-0.0
Free Cash Flow15.9%-16.5-20.8-21.0-21.0-29.8

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)2.63
Basic Shares9.98
Market Cap26.2
Diluted Shares8.62
Fully Diluted Shares Outstanding8.62
Fully Diluted Market Cap22.7
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-31.7
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-5.5

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US